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ABSTRACT
Transforming growth factor b (TGFb) regulates tran-
scriptional responses via activation of cytoplasmic
effectorproteinstermedSmads.Followingtheirphos-
phorylation by the type I TGFb receptor, Smads form
oligomers and translocate to the nucleus where they
activate the transcription of TGFb target genes in
cooperation with nuclear cofactors and coactivators.
In the present study, we have undertaken a deletion
analysis of human Smad3 protein in order to charac-
terize domains that are essential for transcriptional
activation in mammalian cells. With this analysis, we
showed that Smad3 contains two domains with tran-
scriptionalactivationfunction:theMH2domainanda
second middle domain that includes the linker region
andthefirsttwobstrandsoftheMH2domain.Usinga
protein–protein interaction assay based on biotinyla-
tioninvivo,wewereabletoshowthataSmad3protein
bearing aninternal deletion in the middle transactiva-
tion domain is characterized by normal oligomeriza-
tion and receptor activation properties.However, this
mutant has reduced transactivation capacity on syn-
thetic or natural promoters and is unable to interact
physically and functionally with the histone acetyl-
transferase p/CAF. The loss of interaction with
p/CAF or other coactivators could account, at least
in part, for the reduced transactivation capacity of
this Smad3 mutant. Our data support an essential
role of the previously uncharacterized middle region
of Smad3 for nuclear functions, such as transcrip-
tional activation and interaction with coactivators.
INTRODUCTION
Transforming growth factor b (TGFb) controls key biological
processes, including cell proliferation, differentiation,
apoptosis and extracellular matrix production among
others (1,2). All members of the TGFb family of multifunc-
tional ligands signal via heteromeric complexes of type I and
type II serine/threonine kinase receptors. Following binding of
ligands to the receptors, the activated type I receptors are
phosphorylated by the constitutively active type II receptor
kinase and activate, by phosphorylation, intracellular effectors
called receptor-regulated Smads (R-Smads) (3–7). Although
Smad2 and Smad3 act downstream of TGFb and activin
receptors,Smad1,Smad5andSmad8arespeciﬁcallyregulated
by the BMP receptors (5,6). Following activation, R-Smads
translocate to the nucleusas homo- orhetero-oligomers, where
they bind to promoters of target genes and activate their tran-
scription in cooperation with transcriptional cofactors and
coactivators (3–7).
Smads have two conserved functional domains, the
N-terminal Mad Homology 1 (MH1) and the C-terminal
MH2 domains, which are separated by a non-conserved linker
domain. Crystallographic data have shown that the MH1
domain of Smads is globular and compact and is composed
of four a-helices, six short b-sheets, ﬁve loops and a b-hairpin
(8). The b-hairpin structure is involved in DNA binding by
contacting speciﬁc nucleotides present in Smad DNA-binding
elements (SBEs) composed of the tetranucleotide GTCT (8).
The MH1 domain also contains a signal that mediates the
nuclear translocation of Smads and negatively regulates the
functions of the MH2 domain (9–11).
The MH2 domain is indispensable for Smad homo- and
hetero-oligomerization, as well as the recognition and
phosphorylation of R-Smads by their type I receptors (3–7).
Crystallographic studies using puriﬁed Smad2, Smad3 or
Smad4 MH2 domains revealed the formation of a globular
structure with a b-sandwich core element consisting of
twisted antiparallel b-sheets of ﬁve and six strands each
capped by a three-helical bundle (helices H3, H4 and H5)
at one end and a helix–loop region (loops L1, L2, L3 and
helix H1) at the opposite end (12–14). Smad homo- or
hetero-oligomerization is mediated by speciﬁc contacts
between amino acids of the loop–helix region of one MH2
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doi:10.1093/nar/gki679subunit and the a helical bundle of another partner subunit in
the trimer (12). The MH2 trimer was found to have the shape
of a disc with the linker region emerging from one side and the
C-terminal region from the other. Most of the structural ele-
ments of the MH2 domain as well as its overall fold are
conserved among R-Smads. Importantly, point mutations in
highly conserved amino acid residues either in the loop/helix
region or the three-helix bundle of the MH2 domain of Smad4
that disrupt Smad4 oligomerization have been described in
cancer patients (12,15).
In the present study, we have investigated the role of the
middle linker region of Smad3, in various functions charac-
teristic of the R-smad (receptor-regulated Smad) family,
including ligand-stimulated phosphorylation, oligomerization,
nuclear accumulation and transcriptional activation of TGFb
target promoters. Our ﬁndings indicate that the linker region of
Smad3 harbors a potent, ligand-independent, transactivation
domain that has the ability to interact with coactivators and by
synergizing with the C-terminal MH2 transactivation domain
controls the overall transactivation function of the protein in
the nucleus.
MATERIALS AND METHODS
Plasmid constructions
Plasmids expressing the wild-type human Smad3 (amino acids
1–424) or its mutated forms 1–130, 1–230, 1–248, 130–424,
230–424,130–230,130–248,143–248,172–248,201–248and
230–248 were constructed by PCR ampliﬁcation using 50
and 30 primers, speciﬁcally designed to allow the cloning of
the ampliﬁed fragments into the mammalian expression vector
pCDNA1amp-6myc (16) at the EcoRI and NotI sites in frame
with a 6myc epitope tag at the N-terminus. Each cDNA was
excised from the pCDNA1amp-6myc vector and was sub-
cloned into the pBXG1 expression vector in frame with the
DNA-bindingdomain(DBD) ofthe yeast transactivatorGAL4
(amino acids 1–147). The Smad3 mutant bearing the internal
deletion of amino acids 200–230 was constructed by overlap
extension PCR (17). The ampliﬁed fragment corresponding to
the Smad3 internal deletion mutant was cloned ﬁrst into the
pCDNA1amp-6myc vector and then subcloned into the
pBXG1 vector as described above. The sequences of all pri-
mers used in the PCR ampliﬁcations are available upon
request. All mutant Smad3 cDNAs were sequenced for veri-
ﬁcation and found to contain the proper mutation. For the
construction of the yeast expression vectors, the wild-type
Smad3 and the Smad3 143–248 mutant were cloned into
the pAS2-1 vector (Clontech) in frame with the DBD of
GAL4. Plasmid pBS-myc-BirA bearing the myc-tagged
bacterial biotin ligase BirA was a generous gift from
Dr John Strouboulis (Erasmus Medical Center, Rotterdam,
The Netherlands). The BirA gene was subcloned into the
mammalian expression vector pCDNA3 (Invitrogen Life
Technologies). The expression vector pCDNA3-Bio was con-
structed by inserting a double-stranded oligonucleotide linker
with BamHI and EcoRI overhangs coding for the 23 amino
acids biotinylation tag (18) into the corresponding sites of
pCDNA3. Wild-type and mutant forms of Smad3 were tagged
for biotinylation by subcloning their cDNAs into the
pCDNA3-Bio vector in frame with the biotinylation tag.
The expression vector pCDNA3-ﬂag-p/CAF was kindly
offered by Dr I. Talianidis (IMBB-FORTH, Heraklion).
Cell culture and treatments
COS-7, HepG2, NIH3T3, HEK-293T, JEG-3 and MDA-
MB-468 cells were cultured in DMEM, supplemented with
10% fetal bovine serum (FBS) and penicillin–streptomycin, in
a3 7  C, 5% CO2 incubator. Treatment with TGFb1 was for
24 h with a concentration of 200 pM. For the protein stability
experiments, transiently transfected HepG2 cells were treated
with 50 mg/ml of cycloheximide for different time periods and
collected for immunoblotting.
Transient transfections and reporter assays
Transactivation assays were performed by the calcium phos-
phate co-precipitation method in 6-well plates using 1 mgo fa
reporter plasmid and 1–2 mg of expression vectors per well.
b-galactosidase and luciferase assays were performed using
well-established protocols.
Indirect immunofluorescence
Transfected COS-7 cells were seeded on glass coverslips,
coated with 0.1% gelatin. Cells were washed three times on
a slow rotating platform with phosphate-buffered saline+/+
(PBS+/+) (PBS plus 0.9 mM CaCl2 and 0.5 mM MgCl2)
and ﬁxed with 3% p-formaldehyde in PBS+/+ for 5 min at
roomtemperature. Cellswere washedthreetimeswith PBS+/+
and permeabilized with 0.5% Triton X-100 in buffer 1 (10·
buffer 1: 137 mM NaCl, 5 mM KCl, 1 mM Na2HPO4, 0.4 mM
KH2PO4, 5.5 mM glucose, 4 mM NaHCO3, 2 mM MgCl2,
2 mM EDTA, 2 mM EGTA and 20 mM MES, pH 6.0–6.5) for
5minatroomtemperature.Cellswere washedthreetimeswith
PBS+/+, blocked with PBS+/+/1.5% FBS and incubated with
anti-myc (9E10), 1:200 dilution, in PBS+/+/1.5% FBS for 30
min at 4 C. Cells were washed three times with PBS+/+/1.5%
FBS and incubated with the secondary antibody [goat anti-
mouse ﬂuorescein isothiocyanate (FITC), 1:50 dilution in
PBS+/+/1.5% FBS] for 30 min at 4 C in the dark. Cells
were washed three times with PBS+/+ in the dark and mounted
on glass slides using mounting solution (1:1 glycerol/PBS).
Cells were observed using a Leica SP confocal ﬂuorescent
microscope.
In vivo biotinylation and protein–protein interaction
assay
For the in vivo biotinylation assay (18), 7.5 · 10
5 of HEK-
293T cells were transfected in 10 cm dishes with 5 mgo f
pCDNA3-Bio-Smad3 expression vectors (wild-type or mutant
forms) in the presence or in the absence of 7.5 mg of pCDNA3-
BirA vector expressing the bacterial biotin ligase BirA. For
protein–protein interaction assays, HEK-293T cells were co-
transfected with the above plasmids along with 7.5 mgo f
expression vectors pCDNA3-6myc-Smad2, pCDNA3-6myc-
Smad3, pCDNA3-6myc-Smad4 or pCDNA3-ﬂag-p/CAF in
the presence or in the absence of an expression vector for a
constitutively active form of the type I TGFb receptor (ALK5-
ca, 7.5 mg). Cells were lysed in lysis buffer (20 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 10% glycerol and 1% Triton X-100)
and allowed to interact with streptavidin agarose beads for 3 h
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with lysis buffer. Bound proteins as well as the starting
material (input) were subjected to SDS–PAGE followed by
immunoblotting using anti-myc, anti-ﬂag M2 or streptavidin–
HRPandvisualizedbyenhanced chemiluminescenceonX-ray
ﬁlm as described above.
Expression of Smad3 in yeast cells and
functional assays
The Saccharomyces cerevisiae strain pJ694 was a kind gift
from D. Tzamarias (IMBB, Heraklion, Crete). Yeast pJ694
cells were transformed with pAS2-1, pAS2-1-Smad3 wt or
pAS2-1-Smad3 143–248 plasmids using the lithium acetate/
heat-shock protocol. Transformants carrying the desired plas-
mid were selected for growth on minimal YNB medium con-
sisting of 0.67 % yeast nitrogen base (YNB) without amino
acids and 2% glucose (YNBD) supplemented with 0.6% cas-
amino acids, adenine and uracil. Their transactivation capacity
was tested by their growth ability in the following assays: Ade
( ) assay [growth in Ade ( ) plates], AT/His ( ) assays
[growth in His ( ) plates supplemented with 5, 10 or
20 mM AT] and X-gal assay [growth in plates supplemented
with 0.4% X-gal).
RESULTS
The middle region of Smad3 contains a strong
transcriptional activation domain
To identify regions in human Smad3 protein that are essential
for its transcriptional regulatory properties, several truncated
forms of this protein were constructed by PCR ampliﬁcation
and cloned in frame with the DBD of the yeast transactivator
GAL4 (amino acids 1–147). These mutants were expressed
in two different cell lines, the human hepatoma HepG2 cells
and the NIH-3T3 ﬁbroblasts, and assayed for their ability to
transactivate an artiﬁcial promoter (pG5-E1B-luc) consist-
ing of ﬁve tandem GAL4 DNA-binding elements in front
of the minimal adenoviral E1B promoter and the luciferase
reporter gene.
Figure 1. Structure–function analysis of the human Smad3 protein. (A) Schematic representation of the wild-type and various truncated Smad3 forms, fused with
theDBDofGAL4,thatwereutilizedintransactivationexperimentsandtheirrelativetranscriptionalactivityinHepG2andNIH-3T3cells.HepG2orNIH-3T3cells
weretransfectedwiththeindicatedGAL4-Smad3fusionproteinsalongwiththepG5-E1B-LucreporterplasmidandtheCMV-bgalactosidaseplasmid.Thelatterwas
usedfornormalizationoftransfectionvariability.ThenormalizedtranscriptionalactivityofeachGAL4-Smad3proteininHepG2andNIH-3T3cells,relativetothe
activity of the GAL4 alone, which was set to 1, is presented on the right as a mean value (–SEM) of at least three separate experiments performed in duplicate. (B)
Immunoblotting analysis of the different GAL4-Smad3 forms shown in (A) using a monoclonal anti-GAL4 DBD ab. The position of each GAL4-protein is shown
with an asterisk.
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wild-type GAL4-Smad3 protein was  50-fold higher than
the activity of GAL4 DBD alone in both cell lines and was
enhanced further by TGFb stimulation (Figure 1A). TGFb
stimulation was 3.5 times more potent in HepG2 cells than
in NIH-3T3 cells, possibly reﬂecting a difference in the
expression levels of TGFb receptors or other TGFb signaling
regulators between the two cell lines. In contrast, the Smad3
MH1 domain (mutant 1–130) or the MH1 plus the linker
domain (mutant 1–230) had no transcriptional activity. Inter-
estingly, the Smad3 mutant 1–248, which includes the MH1,
thelinkerandasmall18aminoacidregionoftheMH2domain
that includes the ﬁrst and second b strands of this domain, had
high transcriptional activity (28- and 63-fold higher than the
GAL4 DBD alone in HepG2 and NIH-3T3 cells, respectively)
and this activity was independent of TGFb stimulation owing
to the absence of the receptor interaction and phosphorylation
region that resides in the MH2 domain (Figure 1A).
This analysis also showed that the Smad3 mutant 230–424,
which consists of the entire MH2 domain, was as transcrip-
tionally active as wild-type Smad3 and its activity was
enhanced further by TGFb stimulation. Interestingly, the addi-
tion of the linker to the MH2 domain (mutant 130–424)
increased transactivation 3- and 6-fold in HepG2 and NIH-
3T3 cells, respectively (compare the activity of the mutants
130–424 and 230–424), suggesting that the linker domain
should contribute to the transactivation function of Smad3
protein. This was veriﬁed by a different set of Smad3 mutants,
including only the linker region. As shown in Figure 1A,
Smad3 mutant 130–230, which consists of the entire linker
domain, had very low levels of transcriptional activity com-
pared with the activity of wild-type Smad3 (7- and 6-fold in
HepG2 and NIH-3T3, respectively). In contrast, Smad3 mut-
ant 130–248, which consists of the entire linker domain exten-
ded to amino acid 248, had very high levels of transcriptional
activity in both cell lines (148- and 315-fold, respectively)
even in the absence of TGFb stimulation. This strong tran-
scriptional activity was not affected by a small N-terminal
truncation of the linker to amino acid 143 (Smad3 mutant
143–248), but it was decreased and eventually abolished by
progressive N-terminal truncations of the linker to amino acids
172, 201 and 230 (Smad3 mutants 172–248, 201–248 and
230–248, respectively). Immunoblotting analysis showed
that the expression levels of the GAL4-Smad3 truncated
forms used in the transactivation assays of Figure 1A were
comparable (Figure 1B).
In conclusion, using the GAL4 transactivation system that
allows the identiﬁcation and characterization of autonomous
transactivation domains in transcription factors, we were able
to identify a novel, potent and ligand-independent transactiva-
tion domain in the middle region of human Smad3 protein
bounded by amino acids 143 and 248. The minimal region
required for transcriptional activity is between amino acids
200 and 248; thus, we focused our attention to this speciﬁc
region.
An internal deletion of Smad3 in the middle region
severely affected its transcriptional activity
To further investigate the contribution of the middle region of
Smad3 in its transactivation properties, we constructed a
6myc-Smad3 mutant bearing a small internal deletion of
the 200–230 region (Figure 2A). The levels of expression
of this mutant were comparable with the levels of expression
of wild-type Smad3 (Figure 2B). Using the protein synthesis
inhibitor cycloheximide, it was shown that the 30 amino acid
internal deletion of Smad3 did not have any notable effect on
the stability of this protein over a period of 24 h as compared
with the stability of wild-type Smad3 protein and the endo-
genous a-tubulin during the same time period (Figure 2C).
The transcriptional activity of the Smad3 D200–230 mutant
was evaluated by transactivation experiments in the human
JEG-3 choriocarcinoma cell line, which does not express
endogenous Smad3 protein (19). As shown in Figure 2D,
the activity of the Smad-dependent promoter (CAGA)12E1B
consisting of 12 tandem copies of the Smad-binding element
and the minimal adenoviral E1B promoter was nearly back-
ground in these cells both in the absence and in the presence of
the constitutively active ALK5 receptor (ALK5-ca) due to the
lack of endogenous Smad3. Overexpression of wild-type
Smad3 in these cells reconstituted the TGFb signaling path-
way as evidenced by the enhanced (CAGA)12-E1B promoter
activity in the absence and most notably in the presence of
ALK5-ca (Figure 2D). In contrast, very weak promoter stimu-
lation was obtained in JEG-3 cells with the expression vector
for the Smad3 mutant D200–230 and only in the presence of
the ALK5-careceptor(Figure 2D).Thedifference intranscrip-
tional stimulation between the wild-type and the D200–230
mutant in the presence of the ALK5-ca receptor in JEG-3 cells
was  10-fold.
To investigate the ability of the Smad3 D200–230 mutant
to transcriptionally cooperate with Smad4, its activity was
Figure 2. Functional properties of a Smad3 mutant lacking part of the middle region. (A) Schematic representation of wild-type Smad3 and the Smad3 D200-230
mutant, tagged with a 6myc epitope at their N-terminus. Vertical dashed lines and numbers show the coordinates of the internal deletion. (B) HEK293T cells were
transientlytransfectedwithexpressionvectorsforwild-typeSmad3ortheSmad3D200–230mutant,andtheexpressionlevelsofSmad3proteinsweremonitoredby
immunoblottingusingananti-mycmonoclonalantibody.(C)HEK293Tcellsweretransientlytransfectedwithexpressionvectorsforwild-typeSmad3ortheSmad3
D200–230mutant.Thetransfectedcellsweretreatedwiththeproteinsynthesisinhibitorcycloheximide(50mg/ml)forvarioustimeperiods,andtheexpressionlevels
of Smad3 proteins were monitored by immunoblotting using an anti-myc monoclonal antibody. Relative total protein levels were estimated by monitoring
the expression of endogenous a-tubulin. The position of the 6myc-Smad3 proteins and a-tubulin is shown with arrows. The asterisk shows a 6myc-tagged Smad3
(D200–230) mutant with a lower electrophoretic mobility that is possibly derived from the utilization of an alternative translation termination signal. (D) JEG-3
(Smad3 / )choriocarcinomacellsweretransfectedwithexpressionvectorsfor6xmyc-Smad3or6xmyc-Smad3(D200–230)alongwiththep(CAGA)12-E1B-Luc
reporter,intheabsenceorinthepresenceofanexpressionvectorforALK5-ca.Thenormalizedmeanvaluesofluciferaseactivity(–SEM)areshownwithabargraph.
(E) Breast cancer MDA-MB-468 (Smad4  / ) cells were transfected with expression vectors for 6xmyc-Smad3 or 6xmyc-Smad3 (D200–230) along with the
p(CAGA)12-E1B-Luc reporter in the absence or in the presence of an expression vector for 6myc-Smad4 and TGFb (200 pM). The normalized mean values of
luciferase activity (–SEM) are shown with a bar graph. (F and G) Human hepatoma HepG2 cells were transfected with expression vectors for 6xmyc-Smad3 or
6xmyc-Smad3 (D200–230) in the absence or in the presence of an expression vector for 6myc-Smad4 and ALK5-ca and luciferase reporter plasmids bearing the
promoters of the mouse Smad7 gene ( 4200/+110) (F) or the human PAI-1 gene ( 800/+71) (G) as indicated. The normalized mean values of luciferase activity
(–SEM) are shown with bar graphs.
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which lacks endogenous Smad4 expression (20). As shown in
Figure 2E, a strong synergistic transactivation of the
(CAGA)12-E1B promoter was observed by the simultaneous
expression of wild-type Smad3 and Smad4 proteins, whereas
the addition of TGFb did not change the activity of the
(CAGA)12-E1B promoter in a statistically signiﬁcant manner
possibly due to the overexpression of the wild-type Smad
proteins in the transfected MDA-MB-468 cells. Synergistic
transactivation of the (CAGA)12-E1B promoter by the
Smad3 D200–230 mutant and Smad4 was also observed
both in the absence and in the presence of added TGFb, albeit
to lower levels than the corresponding activity of wild-type
Smad3 under the same conditions. The transcriptional activity
of the Smad3 D200–230 mutant was also evaluated on two
natural promoters shown previously to be regulated by the
TGFb signaling pathway, i.e. the promoter of the mouse
Smad7 gene and of the human plasminogen activator
inhibitor 1 (PAI-1) gene (21,22). The activity of Smad7 and
PAI-1 promoters was signiﬁcantly lower in the presence of the
Smad3 D200–230 mutant than in the presence of wild-type
Smad3 either in the presence or in the absence of the ALK5-ca
receptor and Smad4 (Figure 2F and G, respectively).
Similar results were obtained using the GAL4 system. For
the purpose of this experiment, the Smad3 D200–230 mutant
was fused with the DBD of GAL4 (Figure 3A) and used in
transactivation experiments in Smad4 ( / ) MDA-MB-468
cells. As shown in Figure 3B, GAL4-Smad3 wild-type protein
strongly enhanced the activity of the G5-E1B promoter in
MDA-MB-468 cells only in the presence of coexpressed
Smad4 and this Smad3/Smad4 synergism was further poten-
tiated by the addition of TGFb. The GAL4-Smad3 D200–230
mutant was still capable of activating transcription in the pres-
ence of exogenous Smad4 and TGFb, albeit to three times
Figure 3. Deletion of the middle region of Smad3 reduces transactivation in GAL4 assays: (A) Schematic representation of wild-type Smad3 and the Smad3
D200–230mutant,fusedwiththeDBD ofthe yeasttransactivator GAL4attheirN-terminus.Verticaldashedlinesandnumbersshowthecoordinatesoftheinternal
deletion. (B) MDA-MB-468 cells were transfected with GAL4-Smad3 (wt) or GAL4-Smad3 (D200–230) vectors and the pG5-E1B-Luc reporter plasmid in the
absenceorinthepresenceofanexpressionvectorfor6myc-Smad4inthepresenceorintheabsenceof200pMofTGFbasindicatedatthebottomofthegraph.The
relative,normalized,luciferaseactivity(–SEM)ispresentedintheformofabargraph.(C)Immunoblottinganalysisoftransfectedwild-typeandD200–230GAL4-
Smad3 proteins using an anti-GAL4 (DBD) antibody. The arrows show the position of the GAL4-Smad3 proteins.
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ting analysis showed comparable levels of expression of the
wild-type GAL4-Smad3 and the GAL4-Smad3 D200–230
fusion proteins (Figure 3C).
Deletion of the middle region does not affect Smad3
nuclear import
The intracellular localization of wild-type Smad3 and the
Smad3 D200–230 mutant lacking the middle region was ana-
lyzed by indirect immunoﬂuorescence. As shown in Figure 4,
wild-type Smad3 displayed a predominant cytoplasmic local-
ization in the absence of the ALK5-ca receptor, whereas in the
presence of ALK5-ca,Smad3showed prominent nuclear accu-
mulation. Similarly, the Smad3 D200–230 mutant displayed a
cytoplasmic or perinuclear staining in the absence of ALK5-
ca, which became predominantly nuclear in the presence of
ALK5-ca. The data of Figure 4 suggest that the decreased
transactivation efﬁciency of the Smad3 mutant lacking the
200–230 middle region may not be due to a defect in the
TGFb-stimulated nuclear import of this protein.
Deletion of the middle region does not affect Smad3
homo- or heteromerization
To investigate the role of the linker region in Smad3 homo-
and heteromerization, we employed a recently described
protein–protein interaction assay based on protein biotinyla-
tion in vivo (18). The basic principle of our strategy is shown
schematically in Figure 5A. First, we constructed a Smad3
proteinbearing a23amino acidN-terminalpeptide tagthat isa
target for the bacterial biotin ligase BirA (Bio tag, Figure 5A).
This Smad3-Bio fusion protein can be biotinylated in mam-
malian cells by cotransfection with BirA. Biotinylated Smad3
proteins, along with any proteins that interact with it in vivo
such as 6myc-Smad proteins, are subsequently bound to strep-
tavidin agarose beads. Smad3 interacting proteins can be ana-
lyzed by SDS–PAGE and western blotting using the
appropriate antibodies.
First,weexcludedthepossibilitythattheadditionofabiotin
molecule at the N-terminus of Smad3 causes any major dys-
function by showing that the biotinylated Smad3 protein fully
retained its capacity to transactivate the (CAGA)12-E1B pro-
moter in HEK-293T cells (Figure 5B).
Using the biotinylation system just described, we were able
to reproduce a ligand-dependent interaction of Smad3 with
itself (homomerization) or with Smad4 (heteromerization)
in vivo. As shown in Figure 5C, interaction of biotinylated
Smad3 with 6myc-tagged Smad3 in vivo was detected only in
the presence of the biotin ligase BirA and the constitutively
active ALK5-ca receptor (Figure 5C, upper panel, lane 6). The
same was true for the interaction between biotinylated Smad3
and 6myc-tagged Smad4. In this case, a weak interaction
between biotinylated Smad3 and Smad4 was observed in
the absence of the ALK5-ca receptor, but the coexpression
of the receptor signiﬁcantly enhanced the interaction between
the two proteins (Figure 5C, upper panel, compare lanes 8
Figure 4. DeletionofthemiddleregiondoesnotaffectSmad3nuclearaccumulation:COS-7cells weretransfectedwithexpressionvectorsforthewild-type6myc-
Smad3 protein or the Smad3 D200–230 mutant in the absence or in the presence of the constitutively active ALK5 receptor as indicated on the right. Immuno-
fluorescencewasperformedusingtheanti-myc(9E10)monoclonalantibodyfollowedbyasecondary,FITC-conjugated,antibody.Smadproteinswerevisualizedby
fluorescence microscopy. Representative DAPI staining of the transfected cells is also shown.
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cell extracts and on the streptavidin agarose beads and the
expression of 6myc-tagged Smad3 and Smad4 were veriﬁed
by western blotting experiments using streptavidin
conjugated with horseradish peroxidase (HRP) or a mono-
clonal anti-myc antibody (Figure 5C as indicated on the left
of each panel).
Physical interactions between biotinylated Smad3 and
6myc-Smad2 were also demonstrated with the biotinylation
assay. Similar to Smad4, Smad2 interacted weakly with biot-
inylated Smad3 in the absence of the ALK5-ca receptor but
this interaction was enhanced in the presence of the receptor
(Figure 6B, upper panel, compare lanes 2 and 3). In a control
experiment, we showed that the biotinylated Smad3 143–248
mutant that lacks the MH2 domain (Figure 6A) could not
interact with Smad2 either in the absence or in the presence
of ALK5-ca receptor (Figure 6B, upper panel, lanes 5and 6) or
with Smad3 and Smad4 (data not shown).
Having established the validity of the biotinylation assayfor
the analysis of protein–protein interactions in the TGFb path-
way in vivo, we proceeded to analyze the homo- and hetero-
merization properties ofthe Smad3mutant bearingthe internal
deletion D200–230. For this purpose, a new plasmid was con-
structed expressing the Smad3 D200–230 mutant as fusion
Figure 5. Utilizationof an in vivo biotinylationassayto probe the oligomerization propertiesof Smad3.(A) Basicprincipleof the protein–protein interactionassay
based on Smad3 biotinylation in vivo.( B) HEK-293T cells were transfected with pCDNA3-Bio-Smad3 (wt), and the p(CAGA)12-E1B-Luc reporter plasmid in the
absence or presence of an expression vector for biotin ligase BirA as indicated at the bottom of the graph. The relative, normalized, luciferase activity (–SEM) is
presented in the form of a bar graph. (C) HEK-293T cells were transfected with different combinations of expression vectors for Bio, Smad3-Bio, 6myc-Smad3,
6myc-Smad4,BirAandALK5-caasindicatedontop.Theconcentrationsofplasmidsusedandtheprotocoloftheprotein–proteininteractionassayare describedin
detail in Materials and Methods. Western blottings were performed using the anti-myc (9E10) monoclonal antibody for the detection of myc-tagged Smad3 and
Smad4proteins(firstandthirdrow)orHRP-conjugatedstreptavidinforthedetectionofbiotinylatedSmad3protein(secondandfourthrow).Thearrowsontheright
show the position of the indicated proteins. Asterisks show non-specific biotinylated proteins that are detected by streptavidin HRP.
Nucleic Acids Research, 2005, Vol. 33, No. 12 3715Figure 6. Deletion of the middle region does not affect Smad homo- and hetero-oligomerization or phosphorylation by the ALK5 receptor. (A) Schematic
representation of wild-type Smad3-Bio, Smad3 (D200–230)-Bio and the Smad3 (143–248)-Bio proteins used in the oligomerization experiments of (B and C).
(B) HEK-293Tcells were transfected with variouscombinationsof expressionvectors forSmad3-Bio,Smad3(143–248)-Bio, 6myc-Smad2, BirAand ALK5-caas
indicated on top. Western blottings were performed using the anti-myc monoclonal antibody for the detection of myc-tagged Smad2 (first and third row) or HRP-
conjugatedstreptavidinforthedetectionofbiotinylatedSmad3proteins(secondrow).(C)HEK-293Tcellsweretransfectedwithvariouscombinationsofexpression
vectorsforSmad3(D200–230)-Bio,6myc-Smad2,6myc-Smad3,6myc-Smad4,BirAandALK5-caasindicatedontop.Westernblottingswereperformedusingthe
anti-myc monoclonal antibody for the detection of myc-tagged Smad2, Smad3 and Smad4 (first and third row) or HRP-conjugated streptavidin for the detection of
biotinylatedSmad3proteins(secondrow).(D)HEK-293TcellsweretransfectedwithexpressionvectorsforSmad3-BioorSmad3(D200–230)-Biointheabsenceor
in the presence of BirA and ALK5-ca as indicated on top. Proteins bound to the streptavidin agarose beads were analyzed by immunoblotting using a polyclonal
antibody recognizing only the phosphorylated form of Smad3.
3716 Nucleic Acids Research, 2005, Vol. 33, No. 12with the Bio peptide (Figure 6A). As shown in Figure 6C,
efﬁcient, receptor-dependent interactions between the biot-
inylated Smad3 D200–230 mutant and Smad2, Smad3
and Smad4 was observed (upper panel, lanes 3, 6 and 9,
respectively), suggesting that the deletion of the middle region
of Smad3 between amino acids 200 and 230 has no effect on
Smad homo- or heteromerization. Furthermore, the receptor-
dependency of the interactions shown in Figure 6C suggested
that the internal deletion should not affect the interaction of
Smad3 with the type I TGFb receptor. We conﬁrmed this by
showing that both wild-type Smad3 and the D200–230 mutant
are efﬁciently phosphorylated by the ALK5-ca receptor
(Figure 6D, lanes 3 and 6).
Deletion of the 200–230 region affects the physical and
functional interactions between Smad3 and the histone
acetyltransferase p/CAF
To further investigate the mechanism of the transcriptional
inactivation of the Smad3 mutant bearing the internal deletion
D200–230, we analyzed the ability of this mutant to interact
physically and functionally with the histone acetyltransferase
p/CAF. Interactions of Smad3 with this coactivator as well its
homolog GCN5 have been demonstrated previously (23,24).
As shown in Figure 7A, the biotinylated wild-type Smad3
protein interacted with ﬂag-tagged p/CAF in an ALK5-
dependent manner (upper panel, lane 3). In contrast, the biot-
inylated Smad3 D200–230 mutant failed to interact with
p/CAF either in the absence or in the presence of ALK5-ca
(Figure 7A, upper panel, lanes 5 and 6).
To conﬁrm the participation of the middle region of Smad3
in protein–protein interactions with p/CAF, we utilized the
Smad3 143–248 mutant that was shown in Figure 1A to
have high levels of TGFb-independent transcriptional activity.
This analysis showed that the 143–248 mutant interacts
potently with p/CAF even in the absence of stimulation by
the ALK5-ca receptor (Figure 7A, upper panel, lanes 8 and 9).
We also performed GAL4 transactivation assays using the
wild-type Smad3 and the Smad3 mutants D200–230 and 143–
248 in the absence and in the presence of p/CAF. As shown in
Figure 7B, p/CAF enhanced the transcriptional activity of the
wild-type GAL4-Smad3 protein only in the presence of
ALK5-ca. In contrast, p/CAF had no effect on the activity
of the GAL4-Smad3 D200–230 mutant, either in the presence
or in the absence of ALK5-ca, which showed that the inter-
action between Smad3 and p/CAF requires both the 200–230
region and the stimulation by the ALK5-ca receptor. Finally,
p/CAF enhanced the activity of the Smad3 143–248 mutant
again in agreement with the physical interaction data of
Figure 7A.
The middle region of human Smad3 protein is
transcriptionally functional in yeast cells that
lack an endogenous TGFb/Smad pathway
To further explore our ﬁndings regarding the ligand-
independent transcriptional activation function of the middle
region of Smad3, we performed transactivation experiments in
yeast cells that are devoid of an endogenous TGFb/Smad
pathway. For this purpose, wild-type Smad3 and the Smad3
143–248 mutant bearing only the middle region were cloned
into a yeast expression vector as fusions with the DBD of
GAL4 (Figure 8A) and utilized in transactivation experiments
in S.cerevisiae. The results presented in Figure 8B–D estab-
lished that wild-type GAL4-Smad3 and the GAL4-Smad3
143–248 mutant transactivated a GAL4-dependent promoter
linked to various reporter genes, including the b-galactosidase
gene (Figure 8B), the ADE1 gene (Figure 8C) and the HIS3
gene (Figure 8D). Importantly, the GAL4-Smad3 143–248
mutant displayed higher transcriptional activity than wild-
type Smad3 in yeast in accordance with the transactivation
data from HepG2 and NIH-3T3 cells (Figure 1A). Thus, the
transactivation experiments in yeast cells conﬁrmed that the
middle region of Smad3 possesses a strong, ligand-
independent, transcriptional activation function.
Figure 7. Deletion of the middle region abolishes physical and functional
interactions of Smad3 with histone acetyltransferase p/CAF. (A) HEK-293T
cellsweretransfectedwithvariouscombinationsofexpressionvectorsforBio-
Smad3, Bio-Smad3 D200–230, Bio-Smad3 143–248, p/CAF-flag, BirA and
ALK5-ca as indicated on top. The concentrations of plasmids used and the
protocol of the protein–protein interaction assay are described in detail in
Materials and Methods. Western blottings were performed using the anti-
flag monoclonal antibody for the detection of p/CAF (first and third row) or
HRP-conjugated streptavidin for the detection of biotinylated Smad proteins
(second row). WCE, whole cell extract; Strep, streptavidin. (B) HepG2 cells
were transfected with GAL4-Smad3, GAL4-Smad3 (D200–230) or GAL4-
Smad3 (143–248) and the pG5-E1B-Luc reporter plasmid in the absence or
in the presence of an expression vector for ALK5-ca and p/CAF-FLAG as
indicated at the bottom of the graph. The relative, normalized, luciferase
activity (–SEM) is presented in the form of a bar graph.
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In the present study, we have investigated the role of the
middle linker region of Smad3, a key intracellular mediator
of the TGFb signaling pathway, in various functions charac-
teristic of the R-smad (receptor-regulated Smad) family,
including ligand-stimulated phosphorylation, oligomerization,
nuclear accumulation and transcriptional activation of TGFb
target promoters. Our study was facilitated by the generation
of large number of N-terminal, C-terminal and internal trun-
cations of the protein and their utilization in functional assays,
including the well-established GAL4-based transactivation
assay as well as a recently described protein–protein interac-
tion assay (18).
The selection of the GAL4-based assay for our analyses was
based on the following criteria: (i) it allows the identiﬁcation
of autonomous transactivation domains in truncated forms of
multifunctional proteins by their recruitment to a target pro-
moter via an heterologous DBD that does not recognize endo-
genous regulatory elements in mammalian cells; and (ii) it
allows efﬁcient nuclear localization of the tested protein
domains owing to the presence of a nuclear localization signal
inside the DBD of the GAL4 protein. Using this approach, we
were able to show that the middle, non-conserved, linker
domain of Smad3, bounded by amino acids 143 and 248,
harbors a strong, TGFb-independent transcriptional activation
domain that cooperates with the MH2 domain to achieve max-
imal levels of transcriptional activity (Figure 1). The import-
ance of the middle region of Smad3 for transcriptional
activation was also established by showing that a Smad3 mut-
ant bearing an internal deletion of the 200–230 middle region
Figure 8. Wild-type Smad3 and the Smad3 (143–248) mutant are functional in yeast cells. (A) Schematic representation of the yeast expression vectors that
were utilized in the assays of B–D. (B–D) Functional assays which established that GAL4-Smad3 (wt) or GAL4-Smad3 (143–248) mutant are functional in yeast
cells.The assayswerebasedon the abilityoftransformedGAL4-Smad4 (wt)orGAL4-Smad3 (143–248)to activatechromatinincorporatedreportersconsistingof
5 GAL4 binding sites linked to the b-galactosidase gene (B), the ADE1 gene (C) and the HIS3 gene (D). These assays were performed as described in Materials
and Methods.
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200–230 region was selected for further analysis because it
was the minimal region of the linker domain with an auto-
nomoustranscriptionalactivationfunctioninourGAL4assays
(Figure 1A). This deletion did not have any effect on the
stability of Smad3 as shown by the cycloheximide experiment
of Figure 2A.
Using the in vivo biotinylation system, we were able to
reconstitute ligand-dependent homomeric and heteromeric
interactions between Smad proteins and to analyze the effect
of mutations in these interactions. This system is much more
sensitive than the widely used co-immunoprecipitation assay
or the glutathione S-transferase pull-down assay owing to the
extremely high afﬁnity and speciﬁcity of the biotin–
streptavidin interaction. Using a panel of control antibodies,
we could not observe any non-speciﬁc interactions with this
assay. Furthermore, the binding of endogenous biotinylated
proteins to the streptavidin agarose beads, which are clearly
visible in our western blotting assays of Figures 5–7, does not
seem to interfere with the puriﬁcation of Smad3-interacting
proteins.
Using this technology, we showed that the transcriptional
defect of the Smad3 D200–230 mutant could not be attributed
to impaired ligand-dependent phosphorylation by the TGFb
type I receptor (ALK5-ca) or to impaired ligand-dependent
homo- and heteromerization with Smad2 and Smad4
(Figure 6). Furthermore, we established that deletion of the
linker region does not prevent the accumulation of Smad3 in
the nucleus in a ligand-dependent manner (Figure 4).
The transcriptional activity of the middle region of Smad3
could be attributed, at least in part, to its interaction with
nuclear coactivators, such as the histone acetyltransferases
CBP/p300 and p/CAF. We speculated that this region may
play a role analogous to the Smad activation domain
(SAD), a 48 amino acid, proline-rich element within the linker
domain of Smad4 protein, which was shown previously to be
sufﬁcient to activate transcription in GAL4 assays (25). The
transcriptional activity of SAD could be attributed, at least in
part, to its physical and functional interactions with the p300
coactivator (25). In preliminary analyses, we found that the
200–248 region of Smad3 has the potential to interact
physically and functionally with the middle region of the
p300 homologous protein, CREB binding protein (CBP)
and not with the N-terminal region, which is required for
its interaction with the SAD domain of Smad4 (V. Prokova
andD.Kardassis,unpublisheddata). Ourdataareinagreement
with a recent study showing that the linker region of Smad3
(amino acids 143–230) physically and functionally interacts
with the p300 coactivator (26). Amino acid sequence compar-
ison between Smad3 and other R-Smads or Smad4 in the 200–
230 region revealed the conservation of several proline resides
(prolines 205, 209, 214, 223 and 229) as well as of additional
amino acids (leucine 219, glutamine 222 and alanine 230) in
this region that could be important for its function as a trans-
activation domain, but this hypothesis requires further muta-
genesis analysis of these proteins in the above region.
We also found that the middle region of Smad3 has the
ability to interact with the histone acetyltransferase p/CAF,
whereas an internal deletion mutant of Smad3 in this region
abolished its afﬁnity for p/CAF (Figure 7A). These results
seem to contradict previous observations which had shown
that a Smad3 mutant lacking the MH2 domain (Smad3
DMH2) is unable to interact with p/CAF (23). However, we
cannot exclude the possibility that the physical interactions
between our in vivo biotinylated Smad3 linker domain and
p/CAF could be indirect, requiring auxiliary nuclear factors
that bind to the linker region of Smad3.
Although the contribution of the Smad3–p/CAF interaction
for Smad-mediated transcriptional responses in vivo remains
to be established by gene knock-out experiments, it was shown
recently that siRNA-mediated inactivation of the p/CAF
homologous protein gcn5 in mammalian cells affected
Smad3-mediated transactivation (24). This ﬁnding prompted
us to speculate that a similar interaction with the yeast gcn5
(27) could easily account for the high levels of transcriptional
activity of the wild-type Smad3 or the Smad3 143–248 mutant
in S.cerevisiae (Figure 8). Given that a number of yeast tran-
scriptional regulatory proteins, including coactivators, histone
acetyltransferases, such as gcn5, mediator components or
chromatin remodeling enzymes, have their homologs in mam-
malian cells (28–30), we predict that the yeast system could
serve as a valuable tool for the initial identiﬁcation of factors
that participate in evolutionarily conserved Smad-mediated
mechanisms of transcriptional activation.
The middle linker domain of Smad3 contains several serine
residues, some of which have been shown to serve as sites for
phosphorylation by kinases, such as the mitogen-activated
protein kinases Erk, p38 and c-Jun N-terminal kinase,
cyclin-dependent kinases and Ca
2+-calmodulin-dependent
kinase II (31–35). Phosphorylation of the linker region by
the above kinases may regulate several Smad3 functions,
including nuclear accumulation in response to TGFb stimu-
lation.Forinstance,itwasshownthatoncogenicras, actingvia
the Erk MAP kinase, causes phosphorylation of Smad2 and
Smad3 at speciﬁc Ser-Pro motifs in the middle linker region
causing cytoplasmic retention, whereas mutagenesis of these
MAP kinase sites in Smad3 yielded a ras-resistant form that
could rescue the growth inhibitory response to TGFb in Ras-
transformed cells (31). Given that the same region in Smad3
thatcontainsthe above Ser-Promotifs(region 200–230) isalso
required for the transcriptional activity of Smad3 and its inter-
action with coactivators(as shown inthe present study),weare
tempted to speculate that the phosphorylation of these Smad3
motifs by MAP kinases may regulate, in addition to the intra-
cellular distribution, the transactivation function of Smad3
by inﬂuencing its interactions with coactivators or auxiliary
factors that bind to this region.
Finally, our structure–function analysis of Figure 1A
showed that a small region at the N-terminal part of the
MH2 domain is essential for the transactivation function of
linker domain as well as of the MH2 domain (V. Prokova and
D. Kardassis, unpublished data). This region is highly con-
served among the Smad family members, and according to the
crystal structure of Smad4, it includes the ﬁrst two b strands
(b1 and b2) of this domain (Figure 9) (12). This region, being
an integral part of the loop–helix region of the MH2 domain,
may be important for Smad oligomerization. However, this
region by itself is not sufﬁcient to confer oligomerization
properties to the linker domain as shown in the present
study (Figure 6B). Importantly, a single amino acid substitu-
tion within the b1-strand of Smad4 (E330A) was found to be
frequently associated with tumors (15). This speciﬁc amino
Nucleic Acids Research, 2005, Vol. 33, No. 12 3719acid residue is also conserved in the R-Smads, including
Smad1, Smad2 and Smad3 (Figure 9). It is not yet known
whether this speciﬁc mutation in Smad4 is responsible for
loss of TGFb signaling in these tumor cells. Our preliminary
observations showed that the corresponding mutation in
Smad3 severely inhibits its transcriptional activity in
mammalian cells as well its oligomerization properties
(V. Prokova, S. Mavridou and D. Kardassis, unpublished
data) further supporting the important role of this region for
TGFb signaling.
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